- Eli Lilly and Company plans to invest more than $3.5 billion in a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania.
- The site is expected to create 850 permanent jobs, generate about 2,000 construction jobs, and become operational in 2031.
Eli Lilly and Company has announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will be used to produce injectable medicines and devices, including next-generation weight-loss therapies such as retatrutide. The facility will become Lilly’s fourth new U.S. manufacturing site announced since February 2025.
The new site will be located in Fogelsville, Pennsylvania, and was selected from more than 300 applications. Lilly cited the region’s proximity to STEM universities, its technical manufacturing base, and existing infrastructure as key factors. The company also pointed to access to utilities, transportation, zoning, and incentives as supporting factors.
Construction is expected to begin in 2026 and is anticipated to create around 2,000 construction jobs. Once operational in 2031, the facility is expected to employ 850 people, including engineers, scientists, operations staff, and laboratory technicians. Lilly estimates that for every dollar invested, up to four dollars in additional local economic activity could be generated.
The facility will use advanced technologies such as artificial intelligence, machine learning, integrated monitoring, and data analytics to support operations and supply reliability. Lilly also plans to partner with local universities and invest in education across Pennsylvania to support workforce development.
“This investment reflects our commitment to expanding our U.S. manufacturing network to meet growing demand. Lehigh Valley will add capacity for next-generation weight-loss medicines while creating high-quality jobs and strengthening domestic medicine production.”
David A. Ricks, chair and CEO of Lilly
